H.C. Wainwright raised the firm’s price target on Nanobiotix (NBTX) to EUR 23 from EUR 20 and keeps a Buy rating on the shares. The firm believes the company’s “non-dilutive” financing arrangement with HealthCare Royalty brings validation.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- Nanobiotix to Present at Key November Investor Conferences
- Nanobiotix Secures $71 Million Royalty Agreement with HealthCare Royalty
- Nanobiotix enters royalty-based financing pact with HealthCare Royalty for $71M
- Nanobiotix Transfers Phase 3 Trial Control to J&J, Updates on NBTXR3 Program
- Nanobiotix provides update on JNJ-1900 after Johnson & Johnson transfer